Disposition of 26023 shares by Christopher Gibson of Recursion Pharmaceuticals at 6.175 subject to Rule 16b-3
| RXRX Stock | USD 7.80 0.59 8.18% |
Slightly above 55% of Recursion Pharmaceuticals' investors are presently thinking to get in. The analysis of overall sentiment of trading Recursion Pharmaceuticals stock suggests that some investors are interested at this time. Recursion Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Recursion Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Recursion |
Filed transaction by Recursion Pharmaceuticals Director, Officer: Chief Executive Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at investing.com
 |
Recursion Pharmaceuticals Fundamental Analysis
We analyze Recursion Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Recursion Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Recursion Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Recursion Pharmaceuticals is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Recursion Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Recursion Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Recursion Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Recursion Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Recursion Pharmaceuticals Related Equities
| HEPA | Hepion Pharmaceuticals | 30.61 | ||||
| OCEA | Ocean Biomedical | 23.73 | ||||
| ABSI | Absci Corp | 20.30 | ||||
| CNSP | Cns Pharmaceuticals | 9.09 | ||||
| INZY | Inozyme Pharma | 7.72 | ||||
| IMMX | Immix Biopharma | 6.82 | ||||
| SANA | Sana Biotechnology | 3.64 | ||||
| RLAY | Relay Therapeutics | 2.79 | ||||
| ABOS | Acumen Pharmaceuticals | 2.70 | ||||
| ENVB | Enveric Biosciences | 2.56 | ||||
| AFMD | Affimed NV | 0.74 | ||||
| DAWN | Day One | 0.94 | ||||
| XFOR | X4 Pharmaceuticals | 1.33 |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.